AzTrials
AzTrials

Arthritis, RheumatoidPhase 3NCT00847613

A 2-Year Phase 3 Study Of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate

A Phase 3 study testing CP-690,550 in people with Arthritis, Rheumatoid, run by Pfizer at 115 sites in 15 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This study is designed to provide safety and efficacy data to support the development of CP-690,550 in patients with moderate to severe rheumatoid arthritis on background of methotrexate. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Arthritis, Rheumatoid
What is being tested?
CP-690,550
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
800 participants
Where
115 sitesin 15 countries
Study dates
Mar 2009to Feb 2012
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Adults with moderate to severe rheumatoid arthritis on a stable dose of methotrexate

Who cannot join

  • Pregnancy, severe acute or chronic medical conditions, including serious infections or clinically significant laboratory abnormalities.

Trial locations and contacts

115 sites in 15 countries.

115 sites in 15 countries

United States37 sites
  • Pfizer Investigational Site

    Albany, New York, 12206

  • Pfizer Investigational Site

    Baltimore, Maryland, 21224-6821

  • Pfizer Investigational Site

    Bingham Farms, Michigan, 48025

  • Pfizer Investigational Site

    Binghamton, New York, 13905

  • Pfizer Investigational Site

    Clarksburg, West Virginia, 26301

  • Pfizer Investigational Site

    Colorado Springs, Colorado, 80910

  • Pfizer Investigational Site

    Columbia, Missouri, 65203

  • Pfizer Investigational Site

    Columbia, Missouri, 65212

  • Pfizer Investigational Site

    Dallas, Texas, 75231

  • Pfizer Investigational Site

    Dayton, Ohio, 45417

  • Pfizer Investigational Site

    Dubuque, Iowa, 52002

  • Pfizer Investigational Site

    Edina, Minnesota, 55435

  • Pfizer Investigational Site

    Franklin, Wisconsin, 53132

  • Pfizer Investigational Site

    Gainesville, Florida, 32607

  • Pfizer Investigational Site

    Greenville, South Carolina, 29601

  • Pfizer Investigational Site

    Houston, Texas, 77074

  • Pfizer Investigational Site

    Huntsville, Alabama, 35801

  • Pfizer Investigational Site

    Jacksonville, Florida, 32216

  • Pfizer Investigational Site

    Kalamazoo, Michigan, 49048

  • Pfizer Investigational Site

    Knoxville, Tennessee, 37909-1900

  • Pfizer Investigational Site

    Lee's Summit, Missouri, 64086

  • Pfizer Investigational Site

    Lexington, Kentucky, 40536

  • Pfizer Investigational Site

    Morton Grove, Illinois, 60053

  • Pfizer Investigational Site

    Omaha, Nebraska, 68114

  • Pfizer Investigational Site

    Omaha, Nebraska, 68134

  • Pfizer Investigational Site

    Pittsburgh, Pennsylvania, 15213

  • Pfizer Investigational Site

    San Antonio, Texas, 78217

  • Pfizer Investigational Site

    San Diego, California, 92108

  • Pfizer Investigational Site

    Santa Maria, California, 93454

  • Pfizer Investigational Site

    Sarasota, Florida, 34239

  • Pfizer Investigational Site

    Syracuse, New York, 13210

  • Pfizer Investigational Site

    Tampa, Florida, 33614

  • Pfizer Investigational Site

    Tucson, Arizona, 85704

  • Pfizer Investigational Site

    Wheaton, Maryland, 20902

  • Pfizer Investigational Site

    Worcester, Massachusetts, 01605

  • Pfizer Investigational Site

    Wyomissing, Pennsylvania, 19610

  • Pfizer Investigational Site

    Zephyrhills, Florida, 33542

Other trials in United States

Japan14 sites
  • Pfizer Investigational Site

    Bunkyo-ku, Tokyo

  • Pfizer Investigational Site

    Hamamatsu, Shizuoka

  • Pfizer Investigational Site

    Higashihiroshima, Hiroshima

  • Pfizer Investigational Site

    Hitachi-shi, Ibaraki

  • Pfizer Investigational Site

    Kawagoe-shi, Saitama

  • Pfizer Investigational Site

    Kitakyushu, Fukuoka

  • Pfizer Investigational Site

    Koushi, Kumamoto

  • Pfizer Investigational Site

    Ohmura, Nagasaki

  • Pfizer Investigational Site

    Sagamihara, Kanagawa

  • Pfizer Investigational Site

    Sasebo, Nagasaki

  • Pfizer Investigational Site

    Sendai, Miyagi

  • Pfizer Investigational Site

    Shinjuku-ku, Tokyo

  • Pfizer Investigational Site

    Shinjuku-ku, Tokyo

  • Pfizer Investigational Site

    Ureshino-shi, Saga-ken

Other trials in Japan

Canada8 sites
  • Pfizer Investigational Site

    Edmonton, Alberta, T5M 0H4

  • Pfizer Investigational Site

    Hamilton, Ontario, L8N 2B6

  • Pfizer Investigational Site

    Montreal, Quebec, H2L 1S6

  • Pfizer Investigational Site

    Newmarket, Ontario, L3Y 3R7

  • Pfizer Investigational Site

    Québec, Quebec, G1V 3M7

  • Pfizer Investigational Site

    St. John's, Newfoundland and Labrador, A1A 5E8

  • Pfizer Investigational Site

    Toronto, Ontario, M5T 3L9

  • Pfizer Investigational Site

    Victoria, British Columbia, V8V 3P9

Other trials in Canada

Czechia8 sites
  • Pfizer Investigational Site

    Brno, 61300

  • Pfizer Investigational Site

    Brno-Židenice, 615 00

  • Pfizer Investigational Site

    Hostivice, 253 01

  • Pfizer Investigational Site

    Pardubice, 530 02

  • Pfizer Investigational Site

    Prague, 11000

  • Pfizer Investigational Site

    Prague, 128 50

  • Pfizer Investigational Site

    Praha 11 - Chodov, 148 00

  • Pfizer Investigational Site

    Zlín, 760 01

Other trials in Czechia

South Korea8 sites
  • Pfizer Investigational Site

    Daejeon, 302-799

  • Pfizer Investigational Site

    Incheon, 400-711

  • Pfizer Investigational Site

    Seoul, 110-744

  • Pfizer Investigational Site

    Seoul, 120-752

  • Pfizer Investigational Site

    Seoul, 133-792

  • Pfizer Investigational Site

    Seoul, 135-710

  • Pfizer Investigational Site

    Seoul, 137-701

  • Pfizer Investigational Site

    Seoul, 138-736

Other trials in South Korea

Brazil7 sites
  • Pfizer Investigational Site

    Curitiba, Paraná, 80060-240

  • Pfizer Investigational Site

    Goiânia, Goiás, 74110-120

  • Pfizer Investigational Site

    Porto Alegre, Rio Grande do Sul, 90035-903

  • Pfizer Investigational Site

    Porto Alegre, Rio Grande do Sul, 90610-000

  • Pfizer Investigational Site

    Rio de Janeiro, Rio de Janeiro, 22271-100

  • Pfizer Investigational Site

    São Paulo, São Paulo, 04266-010

  • Pfizer Investigational Site

    São Paulo, São Paulo, 05437-010

Other trials in Brazil

India6 sites
  • Pfizer Investigational Site

    Bangalore, Karnataka, 560 034

  • Pfizer Investigational Site

    Bangalore, Karnataka, 560 079

  • Pfizer Investigational Site

    Hyderabad, Andhra Pradesh, 500 004

  • Pfizer Investigational Site

    Mangalore, Karnataka, 575 001

  • Pfizer Investigational Site

    Pune, Maharashtra, 411 001

  • Pfizer Investigational Site

    Secunderabad, Andhra Pradesh, 500003

Other trials in India

Taiwan6 sites
  • Pfizer Investigational Site

    Kaohsiung City, 807

  • Pfizer Investigational Site

    Kweishan, Taoyuan County, 333

  • Pfizer Investigational Site

    Taichung, 407

  • Pfizer Investigational Site

    Tainan, 704

  • Pfizer Investigational Site

    Taipei, 100

  • Pfizer Investigational Site

    Taipei, 112

Other trials in Taiwan

Ukraine5 sites
  • Pfizer Investigational Site

    Kharkiv, 61178

  • Pfizer Investigational Site

    Kyiv, 04114

  • Pfizer Investigational Site

    Lviv, 79011

  • Pfizer Investigational Site

    Simferopol, Autonomous Republic of Crimea, 95017

  • Pfizer Investigational Site

    Vinnitsa, 21018

Other trials in Ukraine

Bulgaria4 sites
  • Pfizer Investigational Site

    Plovdiv, 4000

  • Pfizer Investigational Site

    Plovdiv, 4002

  • Pfizer Investigational Site

    Sofia, 1606

  • Pfizer Investigational Site

    Sofia, 1709

Other trials in Bulgaria

Colombia4 sites
  • Pfizer Investigational Site

    Barranquilla, Atlántico, 0000

  • Pfizer Investigational Site

    Bogota, Cundinamarca

  • Pfizer Investigational Site

    Bucaramanga, Santander Department

  • Pfizer Investigational Site

    Medellín, Antioquia, 0

Other trials in Colombia

Australia3 sites
  • Pfizer Investigational Site

    Malvern East, Victoria, 3145

  • Pfizer Investigational Site

    Maroochydore, Queensland, 4558

  • Pfizer Investigational Site

    Woodville, South Australia, 5011

Other trials in Australia

Mexico2 sites
  • Pfizer Investigational Site

    Mexico City, Mexico City, 14000

  • Pfizer Investigational Site

    Morelia, Michoacán, 58070

Other trials in Mexico

Poland2 sites
  • Pfizer Investigational Site

    Warsaw, 02-256

  • Pfizer Investigational Site

    Wroclaw, 50-088

Other trials in Poland

Greece1 site
  • Pfizer Investigational Site

    Thessaloniki, 54 636

Other trials in Greece

About this study

Official title: Phase 3 Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Of 2 Doses Of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate

This study is designed to provide safety and efficacy data to support the development of CP-690,550 in patients with moderate to severe rheumatoid arthritis on background of methotrexate.

Being tested
CP-690,550, Placebo
Keywords
double-blind placebo-controlled investigational drug oral therapy safety and efficacy hand and feet x-rays
Medical subject headings
Arthritis, Rheumatoid

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • CP-690,550Drug

    Also called Double-blind, placebo-controlled period

    Oral tablets administered at 5 mg BID daily for 6 months (nonresponders advance to second intervention at 3 months) during the double-blind, placebo-controlled period.

  • CP-690,550Drug

    Also called Double-blind, Active Extension Period

    Oral tablets administered at 5 mg BID daily through the end of the study during the double-blind, active-extension period.

  • CP-690,550Drug

    Also called Double-blind, placebo-controlled period

    Oral tablets administered at 10 mg BID daily for 6 months (nonresponders advance to second intervention at 3 months) during the double-blind, placebo-controlled period.

  • CP-690,550Drug

    Also called Double-blind, Active Extension Period

    Oral tablets administered at 10 mg BID daily through the end of the study during the double-blind, active-extension period.

  • PlaceboDrug

    Also called Double-blind, placebo-controlled period

    Oral placebo tablets administered BID daily for 6 months (nonresponders advance to second intervention at 3 months) during the double-blind, placebo-controlled period.

  • CP-690,550Drug

    Also called Double-blind, Active Extension Period

    Oral tablets administered at 5 mg BID daily through the end of the study during the double-blind, active-extension period.

  • PlaceboDrug

    Also called Double-blind, Active Extension Period

    Oral placebo tablets administered BID daily for 6 months (nonresponders advance to second intervention at 3 months) during the double-blind, placebo-controlled period.

  • CP-690,550Drug

    Also called Double-blind, placebo-controlled period

    Oral tablets administered at 10 mg BID daily through the end of the study during the double-blind, active-extension period.

Study groups in NCT00847613
Study groupRoleWhat they receive
Sequence 1ExperimentalNot described
Receives: Drug: CP-690,550
Sequence 2ExperimentalNot described
Receives: Drug: CP-690,550
Sequence 3Placebo comparatorNot described
Receives: Drug: Placebo; Drug: CP-690,550
Sequence 4Placebo comparatorNot described
Receives: Drug: Placebo; Drug: CP-690,550

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Month 6

    ACR20 response: greater than or equal to (>=) 20 percent (%) improvement in tender joint count; >=20% improvement in swollen joint count; and >=20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP). For comparison of CP-690,550 with placebo, placebo sequences were combined into single reporting group for Month 6 analysis.

    Measured: Month 6

  2. Changes From Baseline in Modified Total Sharp Score (mTSS) at Month 6

    mTSS = sum of erosion and Joint Space Narrowing (JSN) scores for 44 joints (16 per hand and 6 per foot). mTSS scores ranged from 0 (normal) to 448 (worst possible total score). Change: scores at observation minus score at baseline. An increase in mTSS from baseline represented disease progression and/or joint worsening, no change represented halting of disease progression, and a decrease represented improvement. For comparison of CP-690,550 with placebo, placebo sequences were combined into single reporting group for Month 6 analysis.

    Measured: Baseline, Month 6

  3. Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Month 3

    HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom, arise, eat, walk, reach, grip, hygiene and common activities over past week. Each item scored on 4-point scale, 0 to 3: 0=no difficulty; 1=some difficulty;2=much difficulty; 3=unable to do. Overall score was computed as sum of domain sc ores and divided by number of domains answered. Total possible score range 0-3: 0=least difficulty and 3=extreme difficulty. For comparison of CP-690,550 with placebo, placebo sequences were combined into single reporting group for Month 3 analysis.

    Measured: Baseline, Month 3

  4. Percentage of Participant With Disease Activity Score Using 28-Joint Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) Less Than 2.6 at Month 6

    DAS28-4 (ESR) calculated from swollen joint count (SJC) and tender/painful joint count (TJC) using 28 joint count, erythrocyte sedimentation rate (ESR) (millimeters per hour [mm/hour]) and patient's global assessment (PtGA) of disease activity (transformed score ranging 0 to 10; higher score indicated greater affectation due to disease activity). Total score range:0 to 9.4, higher score indicated more disease activity. DAS28-4 (ESR) less than or equal to (=<) 3.2 implied low disease activity, greater than (>) 3.2 to 5.1 implied moderate to high disease activity and less than (<) 2.6=remission. For comparison of CP-690,550 with placebo, placebo sequences were combined into single reporting group for Month 6 analysis.

    Measured: Month 6

Secondary outcomes (44)
  1. Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) at Month 1 and 3

    ACR20 response: >=20% improvement in tender joint count; >=20% improvement in swollen joint count; and >=20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of HAQ); and CRP.

    Measured: Month 1, 3

  2. Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) at Month 9, 12, 15, 18, 21 and 24

    ACR20 response: >=20% improvement in tender joint count; >=20% improvement in swollen joint count; and >=20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of HAQ); and CRP.

    Measured: Month 9, 12, 15, 18, 21, 24

  3. Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) at Month 1, 3 and 6

    ACR50 response: greater than or equal to >=50% improvement in tender joint count; >=50% improvement in swollen joint count; and >=50% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of HAQ); and CRP.

    Measured: Month 1, 3, 6

  4. Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) at Month 9, 12, 15, 18, 21 and 24

    ACR50 response: greater than or equal to >=50% improvement in tender joint count; >=50% improvement in swollen joint count; and >=50% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of HAQ); and CRP.

    Measured: Month 9, 12, 15, 18, 21, 24

  5. Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) at Month 1, 3 and 6

    ACR70 response: >=70% improvement in tender joint count; >=70% improvement in swollen joint count; and >=70% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of HAQ); and CRP.

    Measured: Month 1, 3, 6

  6. Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) at Month 9, 12, 15, 18, 21 and 24

    ACR70 response: >=70% improvement in tender joint count; >=70% improvement in swollen joint count; and >=70% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of HAQ); and CRP.

    Measured: Month 9, 12, 15, 18, 21, 24

  7. Disease Activity Score Using 28-Joint Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Baseline, Month 1, 3 and 6

    DAS28-3 (CRP) was calculated from SJC and TJC using 28 joint count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) =<3.2 implied low disease activity, >3.2 to 5.1 implied moderate to high disease activity and <2.6 implied remission.

    Measured: Baseline, Month 1, 3, 6

  8. Disease Activity Score Using 28-Joint Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Month 9, 12, 15, 18, 21 and 24

    DAS28-3 (CRP) was calculated from SJC and TJC using 28 joint count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) =<3.2 indicated low disease activity, >3.2 to 5.1 indicated moderate to high disease activity and <2.6 = remission.

    Measured: Month 9, 12, 15, 18, 21, 24

  9. Disease Activity Score Using 28-Joint Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Baseline, Month 1, 3 and 6

    DAS28-4 (ESR) calculated from SJC and TJC using 28 joint count, ESR (mm/hour) and PGA of disease activity (participant rated arthritis activity assessment with transformed score ranging 0 to 10; higher score indicated greater affectation due to disease activity). Total score range:0 to 9.4, higher score indicated more disease activity. DAS28-4 (ESR) =<3.2 implied low disease activity, >3.2 to 5.1 implied moderate to high disease activity and <2.6 implied remission.

    Measured: Baseline, Month 1, 3, 6

  10. Disease Activity Score Using 28-Joint Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Month 9, 12, 15, 18, 21 and 24

    DAS28-4 (ESR) calculated from SJC and TJC using 28 joint count, ESR (mm/hour) and PtGA of disease activity (participant rated arthritis activity assessment with transformed score ranging 0 to 10; higher score indicated greater affectation due to disease activity). Total score range:0 to 9.4, higher score indicated more disease activity. DAS28-4 (ESR) =<3.2 implied low disease activity, >3.2 to 5.1 implied moderate to high disease activity and <2.6 implied remission.

    Measured: Month 9, 12, 15, 18, 21, 24

  11. Disease Activity Score Using 28-Joint Count and C-Reactive Protein (4 Variables) (DAS28-4 [CRP])

    DAS28-4 (CRP) was calculated from SJC and TJC using the 28 joints count, CRP [mg/L] and PtGA of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-4 [CRP] <=3.2 implied low disease activity, DAS28-4 [CRP] >3.2 to 5.1 implied moderate to high disease activity and DAS28 <2.6 implied remission.

    Measured: Baseline, Month 1, 3, 6, 9, 12, 15, 18, 21, 24

  12. Disease Activity Score Using 28-Joint Count and Erythrocyte Sedimentation Rate (3 Variables) (DAS28-3 [ESR])

    DAS28-3 (ESR) was calculated from the number of SJC and TJC using the 28 joints count and ESR (mm/hr). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (ESR) <=3.2 implied low disease activity, >3.2 to 5.1 implied moderate to high disease activity and <2.6 implied remission.

    Measured: Baseline, Month 1, 3, 6, 9, 12, 15, 18, 21, 24

  13. Modified Total Sharp Scores (mTSS) at Baseline

    mTSS = sum of erosion and JSN scores for 44 joints (16 per hand and 6 per foot). mTSS scores ranged from 0 (normal) to 448 (worst possible total score). An increase in mTSS from baseline represented disease progression and/or joint worsening, no change represented halting of disease progression, and a decrease represented improvement.

    Measured: Baseline

  14. Modified Total Sharp Scores (mTSS) at Month 12 and 24

    mTSS = sum of erosion and JSN scores for 44 joints (16 per hand and 6 per foot). mTSS scores ranged from 0 (normal) to 448 (worst possible total score). An increase in mTSS from baseline represented disease progression and/or joint worsening, no change represented halting of disease progression, and a decrease represented improvement.

    Measured: Month 12, 24

  15. Health Assessment Questionnaire Disability Index (HAQ-DI) at Baseline, Month 1, 3 and 6

    HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0=least difficulty and 3=extreme difficulty.

    Measured: Baseline, Month 1, 3, 6

  16. Health Assessment Questionnaire Disability Index (HAQ-DI) at Month 9, 12, 15, 18, 21 and 24

    HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0=least difficulty and 3=extreme difficulty.

    Measured: Month 9, 12, 15, 18, 21, 24

  17. Patient Assessment of Arthritis Pain at Baseline, Month 1, 3 and 6

    Participants rated the severity of arthritis pain on a 0 to 100 millimeter (mm) visual analogue scale (VAS), where 0 mm = no pain and 100 mm = most severe pain.

    Measured: Baseline, Month 1, 3, 6

  18. Patient Assessment of Arthritis Pain at Month 9, 12, 15, 18, 21 and 24

    Participants rated the severity of arthritis pain on a 0 to 100 mm visual analogue scale (VAS), where 0 mm = no pain and 100 mm = most severe pain.

    Measured: Month 9, 12, 15, 18, 21, 24

  19. Patient Global Assessment (PtGA) of Arthritis Pain at Baseline, Month 1, 3, and 6

    Participants answered: "Considering all the ways your arthritis affects you, how are you feeling today?" Participants responded by using a 0 - 100 mm VAS where 0 = very well and 100 = very poorly.

    Measured: Baseline, Month 1, 3, 6

  20. Patient Global Assessment (PtGA) of Arthritis Pain at Month 9, 12, 15, 18, 21 and 24

    Participants answered: "Considering all the ways your arthritis affects you, how are you feeling today?" Participants responded by using a 0 - 100 mm VAS where 0 = very well and 100 = very poorly.

    Measured: Month 9, 12, 15, 18, 21, 24

  21. Physician Global Assessment (PGA) of Arthritis at Baseline, Month 1, 3 and 6

    Physician Global Assessment of Arthritis was measured on a 0 to 100 mm VAS, where 0 mm = very good and 100 mm = very bad.

    Measured: Baseline, Month 1, 3, 6

  22. Physician Global Assessment (PGA) of Arthritis at Month 9, 12, 15, 18, 21 and 24

    Physician Global Assessment of Arthritis was measured on a 0 to 100 mm VAS, where 0 mm = very good and 100 mm = very bad.

    Measured: Month 9, 12, 15, 18, 21, 24

  23. 36-Item Short-Form Health Survey (SF-36) at Baseline, Month 1, 3 and 6

    SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and is reported as 2 summary scores; physical component score and mental component score. Total score range for the summary scores = 0-100, where higher score represents higher level of functioning.

    Measured: Baseline, Month 1, 3, 6

  24. 36-Item Short-Form Health Survey (SF-36) at Month 9, 12, 15, 18, 21 and 24

    SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and is reported as 2 summary scores; physical component score and mental component score. Total score range for the summary scores = 0-100, where higher score represents higher level of functioning.

    Measured: Month 9, 12, 15, 18, 21, 24

  25. Medical Outcomes Study Sleep Scale (MOS-SS) at Baseline, Month 1, 3 and 6

    Participant-rated 12 item questionnaire to assess constructs of sleep over past week.7 subscales: sleep disturbance, snoring, awakened short of breath, sleep adequacy, somnolence (range:0-100); sleep quantity(range:0-24), optimal sleep(yes or no). 9 item index measures of sleep disturbance provide composite scores: sleep problem summary, overall sleep problem. Except Adequacy, Optimal, Quantity of sleep, higher scores=more impairment. Scores transformed(actual raw score(RS) minus lowest possible score divided by possible RS range*100);total score range:0-100,higher score=more intensity of attribute.

    Measured: Baseline, Month 1, 3, 6

  26. Number of Participants With Optimal Sleep Assessed Using Medical Outcomes Study Sleep Scale (MOS-SS) at Baseline, Month 1, 3 and 6

    MOS-SS: participant-rated 12 item questionnaire to assess constructs of sleep over past week. It included 7 subscales: sleep disturbance, snoring, awakened short of breath, sleep adequacy, somnolence, sleep quantity and optimal sleep. Participants responded whether their sleep was optimal or not by choosing yes or no. Number of participants with optimal sleep are reported.

    Measured: Baseline, Month 1, 3, 6

  27. Medical Outcomes Study Sleep Scale (MOS-SS) at Month 12, 18 and 24

    Participant-rated 12 item questionnaire to assess constructs of sleep over past week.7 subscales: sleep disturbance, snoring, awakened short of breath, sleep adequacy, somnolence (range:0-100); sleep quantity(range:0-24), optimal sleep(yes or no). 9 item index measures of sleep disturbance provide composite scores: sleep problem summary, overall sleep problem. Except Adequacy, Optimal, Quantity of sleep, higher scores=more impairment. Scores transformed(actual raw score(RS) minus lowest possible score divided by possible RS range*100);total score range:0-100,higher score=more intensity of attribute.

    Measured: Month 12, 18, 24

  28. Number of Participants With Optimal Sleep Assessed Using Medical Outcomes Study Sleep Scale (MOS-SS) at Month 12, 18 and 24

    MOS-SS: participant-rated 12 item questionnaire to assess constructs of sleep over past week. It included 7 subscales: sleep disturbance, snoring, awakened short of breath, sleep adequacy, somnolence, sleep quantity and optimal sleep. Participants responded whether their sleep was optimal or not by choosing yes or no. Number of participants with optimal sleep are reported.

    Measured: Month 12, 18, 24

  29. Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Baseline, Month 1, 3, and 6

    FACIT-Fatigue is a 13-item questionnaire. Participant scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as 4 minus the participant's response. The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). A higher score reflected an improvement in the participant's health status.

    Measured: Baseline, Month 1, 3, 6

  30. Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Month 12, 18 and 24

    FACIT-Fatigue is a 13-item questionnaire. Participant scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as 4 minus the participant's response. The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). A higher score reflected an improvement in the participant's health status.

    Measured: Month 12, 18, 24

  31. Euro Quality of Life (EQ-5D)- Health State Profile Utility Score at Baseline, Month 3 and 6

    EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.

    Measured: Baseline, Month 3, 6

  32. Euro Quality of Life (EQ-5D)- Health State Profile Utility Score at Month 12, 18 and 24

    EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.

    Measured: Month 12, 18, 24

  33. Work Limitations Questionnaire (WLQ) Score at Baseline, Month 3 and 6

    WLQ: participant-reported 25-item scale to evaluate degree to which health problems interfere with an ability to perform job roles along 4 dimensions: Time Management scale (5-items); Physical Demands scale (6-item); Mental-Interpersonal Demands Scale (9-items); Output Demands scale (5-items). All the scales ranged from 0 (limited none of the time) to 100 (limited all of the time). Work Loss Index, which represented percentage of lost work over time period relative to a normative population, was derived (total score:0[no loss] to 100[complete loss of work]).

    Measured: Baseline, Month 3, 6

  34. Work Limitations Questionnaire (WLQ) Score at Month 12, 18 and 24

    WLQ: participant-reported 25-item scale to evaluate degree to which health problems interfere with an ability to perform job roles along 4 dimensions: Time Management scale (5-items); Physical Demands scale (6-item); Mental-Interpersonal Demands Scale (9-items); Output Demands scale (5-items). All the scales ranged from 0 (limited none of the time) to 100 (limited all of the time). Work Loss Index, which represented percentage of lost work over time period relative to a normative population, was derived (total score:0[no loss] to 100[complete loss of work]).

    Measured: Month 12, 18, 24

  35. Work Productivity and Healthcare Resource Utilization (HCRU) at Baseline, Month 3 and 6

    Rheumatoid Arthritis (RA)-HCRU assessed healthcare usage during last 3 months for direct, indirect medical cost domains. Direct cost: visit to doctor, non-medical practitioner, nursing home, hospital, surgery, emergency room(ER) treatment, diagnostic tests, over-night stay, home healthcare services, aids/devices used. Indirect costs associated with functional disability: employment status, willingness to work, work disability due to RA, sick leave, part time work, ability to perform chores, chores done by family, friends or housekeeper. Assessment was based on 0 to 2-point scale; higher score=higher medical cost.

    Measured: Baseline, Month 3, 6

  36. Work Productivity and Healthcare Resource Utilization (HCRU) at Month 12, 18 and 24

    Rheumatoid Arthritis (RA)-HCRU assessed healthcare usage during last 3 months for direct, indirect medical cost domains. Direct cost:visit to doctor,non-medical practitioner,nursing home,hospital,surgery,emergency room(ER) treatment,diagnostic tests, over-night stay,home healthcare services, aids/devices used. Indirect costs associated with functional disability:employment status,willingness to work,work disability due to RA,sick leave,part time work,ability to perform chores,chores done by family/friends/housekeeper. Assessment was based on 0 to 2-point scale;higher score=higher medical cost.

    Measured: Month 12, 18, 24

  37. Number of Events Including Visits, Surgeries, Tests or Devices as Assessed Using RA-HCRU at Baseline, Month 3 and 6

    RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains. Any RA/non-RA related number of events including visits to doctor, non-medical practitioner, hospital ER treatment, hospitalizations, number of surgeries, diagnostic tests, and devices/aids used were reported.

    Measured: Baseline, Month 3, 6

  38. Number of Events Including Visits, Surgeries, Tests or Devices as Assessed Using RA-HCRU at Month 12, 18 and 24

    RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains. Any RA/non-RA related number of events including visits to doctor, non-medical practitioner, hospital ER treatment, hospitalizations, number of surgeries, diagnostic tests, and devices/aids used were reported.

    Measured: Month 12, 18, 24

  39. Number of Days as Assessed Using RA-HCRU at Baseline, Month 3 and 6

    RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains.Any RA or non-RA related number of days spent in hospital, nursing home, aids/devices used, on sick leave, work per week, performed part time work, performed paid work, chores done by housekeeper and chores done by family/friends.

    Measured: Baseline, Month 1, 3, 6

  40. Number of Days as Assessed Using RA-HCRU at Month 12, 18 and 24

    RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains.Any RA or non-RA related number of days spent in hospital, nursing home, aids/devices used, on sick leave, work per week, performed part time work, performed paid work, chores done by housekeeper and chores done by family/friends.

    Measured: Month 12, 18, 24

  41. Number of Hours Per Day as Assessed RA-HCRU at Baseline, Month 3 and 6

    RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains. Any RA or non-RA related number of hours spent per day for home healthcare services, chores done by housekeeper, chores done by family or friends, work done and work missed were reported.

    Measured: Baseline, Month 1, 3, 6

  42. Number of Hours Per Day as Assessed RA-HCRU at Month 12, 18 and 24

    RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains. Any RA or non-RA related number of hours spent per day for home healthcare services, chores done by housekeeper, chores done by family or friends, work done and work missed were reported.

    Measured: Month 12, 18, 24

  43. Work Performance in Past 3 Months on Days Bothered as Assessed Using RA-HCRU at Baseline, Month 3 and 6

    Work performance of participants on number of days bothered was based on a 0 to 10-point scale, where higher score indicated lower work performance.

    Measured: Baseline, Month 1, 3, 6

  44. Work Performance in Past 3 Months on Days Bothered as Assessed Using RA-HCRU at Month 12, 18 and 24

    Work performance of participants on number of days bothered was based on a 0 to 10-point scale, where higher score indicated lower work performance.

    Measured: Month 12, 18, 24

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 Feb 2009 (estimated)
  2. Study startMar 2009
  3. Primary completionApr 2011
  4. Study completionFeb 2012

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
800 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00847613
Sponsor's protocol ID
A3921044
Status last verified
Apr 2024
First submitted
17 Feb 2009
Last updated
16 May 2024
Data monitoring committee
Yes

Publications

  • Wright G, Mysler E, Roberts KD, Shelbaya A, Sweet L, Masri KR. Impact of the Sociodemographic Index on Efficacy/Safety of Tofacitinib in Patients with Rheumatoid Arthritis: Post Hoc Analysis of Phase 2/3/3b/4 Studies. Rheumatol Ther. 2026 Oct 16. doi: 10.1007/s40744-026-00881-y. Online ahead of print.

    PubMed 42888330
  • Strand V, Schulze-Koops H, Al-Emadi S, Kinch CD, Gruben D, Germino R, Connell CA, Mysler E. Sex differences in the efficacy, safety and persistence of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of phase III and long-term extension trials. BMJ Open. 2025 Dec 24;15(12):e082366. doi: 10.1136/bmjopen-2023-082366.

    PubMed 41448717
  • Hetland ML, Strangfeld A, Bonfanti G, Soudis D, Deuring JJ, Edwards RA. Machine learning prediction and explanatory models of serious infections in patients with rheumatoid arthritis treated with tofacitinib. Arthritis Res Ther. 2024 Aug 27;26(1):153. doi: 10.1186/s13075-024-03376-9.

    PubMed 39192350
  • Wright GC, Mysler E, Kwok K, Cadatal MJ, Germino R, Yndestad A, Kinch CD, Ogdie A. Impact of Race on the Efficacy and Safety of Tofacitinib in Rheumatoid Arthritis: Post Hoc Analysis of Pooled Clinical Trials. Rheumatol Ther. 2024 Oct;11(5):1135-1164. doi: 10.1007/s40744-024-00677-y. Epub 2024 Jul 3.

    PubMed 38958913
  • Citera G, Jain R, Irazoque F, Madariaga H, Gruben D, Wang L, Stockert L, Santana K, Ebrahim A, Ponce de Leon D. Tofacitinib Efficacy in Patients with Rheumatoid Arthritis and Probable Depression/Anxiety: Post Hoc Analysis of Phase 3 and 3b/4 Randomized Controlled Trials. Rheumatol Ther. 2024 Feb;11(1):35-50. doi: 10.1007/s40744-023-00612-7. Epub 2023 Nov 5.

    PubMed 37925660
  • Charles-Schoeman C, Hyde C, Guan S, Parikh N, Wang J, Shahbazian A, Stockert L, Andrews J. Relationship Between Paraoxonase-1 Genotype and Activity, and Major Adverse Cardiovascular Events and Malignancies in Patients With Rheumatoid Arthritis Receiving Tofacitinib. J Rheumatol. 2023 Jul 15:jrheum.2023-0112. doi: 10.3899/jrheum.2023-0112. Online ahead of print.

    PubMed 37453736
  • Kristensen LE, Danese S, Yndestad A, Wang C, Nagy E, Modesto I, Rivas J, Benda B. Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance. Ann Rheum Dis. 2023 Jul;82(7):901-910. doi: 10.1136/ard-2022-223715. Epub 2023 Mar 17.

    PubMed 36931693
  • Dougados M, Taylor PC, Bingham CO 3rd, Fallon L, Brault Y, Roychoudhury S, Wang L, Kessouri M. The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis. RMD Open. 2022 Sep;8(2):e002478. doi: 10.1136/rmdopen-2022-002478.

    PubMed 36814062
  • Hansen KE, Mortezavi M, Nagy E, Wang C, Connell CA, Radi Z, Litman HJ, Adami G, Rossini M. Fracture in clinical studies of tofacitinib in rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2022 Dec 27;14:1759720X221142346. doi: 10.1177/1759720X221142346. eCollection 2022.

    PubMed 36601090
  • Curtis JR, Yamaoka K, Chen YH, Bhatt DL, Gunay LM, Sugiyama N, Connell CA, Wang C, Wu J, Menon S, Vranic I, Gomez-Reino JJ. Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial. Ann Rheum Dis. 2023 Mar;82(3):331-343. doi: 10.1136/ard-2022-222543. Epub 2022 Dec 5.

    PubMed 36600185
  • Winthrop KL, Yndestad A, Henrohn D, Danese S, Marsal S, Galindo M, Woolcott JC, Jo H, Kwok K, Shapiro AB, Jones TV, Diehl A, Su C, Panes J, Cohen SB. Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs. Rheumatol Ther. 2023 Apr;10(2):357-373. doi: 10.1007/s40744-022-00507-z. Epub 2022 Dec 17.

    PubMed 36526796
  • Dikranian AH, Gonzalez-Gay MA, Wellborne F, Alvaro-Gracia JM, Takiya L, Stockert L, Paulissen J, Shi H, Tatulych S, Curtis JR. Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by baseline body mass index: an analysis of pooled data from phase 3 studies. RMD Open. 2022 May;8(1):e002103. doi: 10.1136/rmdopen-2021-002103.

    PubMed 35577477
  • Bartlett SJ, Bingham CO, van Vollenhoven R, Murray C, Gruben D, Gold DA, Cella D. The impact of tofacitinib on fatigue, sleep, and health-related quality of life in patients with rheumatoid arthritis: a post hoc analysis of data from Phase 3 trials. Arthritis Res Ther. 2022 Apr 5;24(1):83. doi: 10.1186/s13075-022-02724-x.

    PubMed 35382883
  • Dikranian A, Gold D, Bessette L, Nash P, Azevedo VF, Wang L, Woolcott J, Shapiro AB, Szumski A, Fleishaker D, Wollenhaupt J. Frequency and Duration of Early Non-serious Adverse Events in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Treated with Tofacitinib. Rheumatol Ther. 2022 Apr;9(2):411-433. doi: 10.1007/s40744-021-00405-w. Epub 2021 Dec 17.

    PubMed 34921355
  • Winthrop KL, Curtis JR, Yamaoka K, Lee EB, Hirose T, Rivas JL, Kwok K, Burmester GR. Clinical Management of Herpes Zoster in Patients With Rheumatoid Arthritis or Psoriatic Arthritis Receiving Tofacitinib Treatment. Rheumatol Ther. 2022 Feb;9(1):243-263. doi: 10.1007/s40744-021-00390-0. Epub 2021 Dec 6.

    PubMed 34870800

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing CP-690,550 in people with Arthritis, Rheumatoid, run by Pfizer at 115 sites in 15 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 16 May 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 115 sites in United States, Japan, Canada, Czechia, South Korea and 10 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 9 Jan 2013). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Month 6 (time frame: Month 6). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00847613, which also lists 27 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 May 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in